Peer-reviewed veterinary case report
Pullulan-conjugated Der f 2 immunotherapy for dog atopic dermatitis
By Kawano, Kouji & Mizuno, Takuya·Published in Veterinary Dermatology·2017·Primo Animal Hospital Tokyo Animal Allergy Medical Center (AAMC) 1‐28‐7 Shakujiimachi Nerima‐Ku Tokyo 177‐0041 Japan, Japan·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis
- Species:
- dog
Plain-English summary
A group of dogs with atopic dermatitis, a skin condition causing itching and irritation, were treated with a new immunotherapy made from a dust mite allergen called Der f 2. Over the course of the study, the dogs showed significant improvement in their skin condition and itching levels after receiving the treatment. The amount of oral steroids needed to manage their symptoms also decreased, indicating that the new therapy was effective. Overall, this treatment could be a promising option for dogs suffering from allergies related to dust mites.
People also search for: dog itching treatment · atopic dermatitis in dogs · Der f 2 immunotherapy for dogs
Abstract
BackgroundDermatophagoides farinae is a major and common environmental house dust mite involved in canine atopic dermatitis (CAD). A formulation of recombinant protein Der f 2 is available in Japan for immunotherapy in dogs.Hypothesis/ObjectivesTo evaluate the efficacy of a recombinant allergen based on Der f 2‐pullulan for the treatment of cAD.MethodsDogs (n = 15) with atopic dermatitis were administered Der f 2 conjugated with pullulan (‐P). Two dogs were eliminated because of death unrelated to the treatment during the study. The remaining 13 cases were included in the analysis. Clinical signs were evaluated with the Canine Atopic Dermatitis Lesion Index (CADLI) and pruritus levels were evaluated from 0 to 10 with a pruritus Visual Analog Scale (PVAS).ResultsThe mean ± standard deviation (SD) of CADLI [before allergen‐specific immunotherapy (pre‐ASIT) 21.9 ± 9.7; 60 days post‐ASIT 9.8 ± 8.4 and 120 days post‐ASIT 9.7 ± 8.2] and the mean ± SD of PVAS [pre‐ASIT 7.2 ± 1.2; post‐ASIT (60 days) 2.6 ± 2.2 and post‐ASIT (120 days) 3.1 ± 2.5] significantly decreased after treatment (Dunnett's test, P < 0.05). Furthermore, the total doses of oral glucocorticoids in the two months pre‐ASIT significantly decreased in comparison with two months post‐ASIT (123 ± 72.6 mg vs. 70.0 ± 84.3 mg; Dunnett's test, P < 0.05).Conclusions and clinical importanceThe results indicate the effectiveness of Der f 2‐P recombinant protein in the treatment of dogs with CAD and testing positive to D. farinae.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vde.12470